Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Highlights From the 2021 SABCS Symposium
  • CME

Joyce O'Shaughnessy, MD
Sara Tolaney, MD, MPH
Released: February 25, 2022
Back Next

References

  1. Bardia A, Neven P, Streich G, et al. Elacestrant, an oral selective estrogen receptor degrader vs investigator’s choice of endocrine monotherapy for ER+/HER2– advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy: results of EMERALD phase 3 trial. Presented at: San Antonio Breast Cancer Symposium; December 7-10, 2021. Abstract GS2-02.
  2. Lindeman G, Bowen R, Jerzak KJ, et al. Results from VERONICA: a randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC). Presented at: American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 1004.
  3. Chandarlapaty S, Linden HM, Neven P, et al. Updated data from AMEERA-1: phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer. Presented at: San Antonio Breast Cancer Symposium; December 7-10, 2021. Abstract P1-17-11.
  4. Chandarlapaty S, Linden HM, Neven P, et al. AMEERA-1: phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). Presented at: American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 1058.
  5. O’Shaughnessy J, Stemmer SM, Burris HA, et al. Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer. Presented at: San Antonio Breast Cancer Symposium; December 7-10, 2021. Abstract GS2-01.
  6. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB). Presented at: European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA17-PR.
  7. Carey L, Solovieff N, André F, et al. Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer. Presented at: San Antonio Breast Cancer Symposium; December 7-10, 2021. Abstract GS2-00.
  8. Prat A, Chaudhury A, Solovieff N, et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies. J Clin Oncol. 2021;39:1458-1467.
  9. Schmid P, Cortés J, Dent R, et al. KEYNOTE-522: phase III study of neoadjuvant pembrolizumab and chemotherapy vs. placebo and chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early stage TNBC. Presented at: ESMO Virtual Plenary; July 15-16, 2021. Abstract VP7-2021.
  10. Schmid P, Cortés J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
  11. Schmid P, Cortés J, Dent R, et al. KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: event-free survival sensitivity and subgroup analyses. Presented at: San Antonio Breast Cancer Symposium; December 7-10, 2021. Abstract GS1-01.
  12. Cortés J, Cescon DW, Rugo HS, et al. Final results of KEYNOTE-355: randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Presented at: San Antonio Breast Cancer Symposium; December 7-10, 2021. Abstract GS1-02.
  13. Cortés J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:P1817-1828.
  14. Rugo HS, Cortés J, Cescon DW, et al. KEYNOTE-355: final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Presented at: European Society for Medical Oncology Congress; September 19, 2021. Abstract LBA16.
  15. Krop I, Juric D, Shimizu T, et al. Datopotamab deruxtecan (Dato-DXd) in advanced/metastatic HER2 negative breast cancer: triple negative breast cancer results from the phase 1 TROPION-PanTumor01 study. Presented at: San Antonio Breast Cancer Symposium; December 7-10, 2021. Abstract GS1-05.
  16. Murthy R, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609.
  17. Lin UL, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610-2619.
  18. Curigliano G, Mueller V, Borges VF, et al. Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Presented at: American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 1043.
  19. Lin NU, Murthy RK, Abramson V, et al. Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB). Presented at: San Antonio Breast Cancer Symposium; December 7-10, 2021. Poster PD4-04.
  20. Hurvitz S, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer: results of the randomized phase 3 study DESTINY-Breast03. Presented at: San Antonio Breast Cancer Symposium; December 7-10, 2021. Abstract GS3-01.
  21. Murthy RK, O'Brien B, Berry DA, et al. Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: results from TBCRC049, a phase 2 non-randomized study. Presented at: San Antonio Breast Cancer Symposium; December 7-10, 2021. Poster PD4-02.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Novartis Pharmaceuticals Corporation
Sanofi Genzyme
Seagen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings